Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.
Back
Pegcrisantaspase Combo Offers Potential to Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML
Ashkan Emadi, MD, PhD, discusses the scientific rationale for this venetoclax plus pegcrisantaspase and preclinical data that supported the phase 1 study; detailed the findings from the phase 1 trial; and explained the potential role for this regimen in the management of acute myeloid leukemia.
Pegcrisantaspase Combo Offers Potential to Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML
Episodes
All
All
Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.
The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5